Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
P53 and chemo agent resistance re EGFR
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229180/
I asked if I could buy with a broker and I cannot as they cannot see bid ask
I cannot buy in my retirement brokerage account without bid ask
I can't place a trade because of this
Why is there no body or ask posted on the major sites like Google finance or yahoo finance?
I did not mean this stock is a speculative play, it has been greatly derisked with the positive results from the brilicidin,prurisol and kevetrin trials. I meant that the reason for not disclosing the location of the ulcerative proctitis trial is my personal speculation or conjecture .
In fact I feel this company has the potential to be a phenomenal story, and that all currant investors may have latched onto the equivalent of a Microsoft in 1986, or an Amazon in 1997. We basically are in at a great price in a company that has a great future with potential to help the eorld deal with major problems such as cancer, antibiotic resistance etc. One day people may also wish they had invested in Cellceutix in 2016 before what I believe will be an eventual meteoric rise in price.
Re: Ulcerative proctitis trial site
It is interesting that we have not been given any information about the site where the ulcerative proctitis trial has been initiated. We know it is in a country that required ministry of health approval in order to commence. Could it be that an international pharma wants to directly monitor the response to treatment before offering a partnership and that management and the pharma are keeping this quiet? For example, if the trial was taking place in Basel Switzerland, there would be great speculation about a Roche or Norvartis partnership, and if it was taking place in Paris there might be speculation about a Sanofi partnership. This is all speculative, we will likely know more about this trial within a few months.
To change the current topic
Could Kevetrin have a role in the treatment of another terrible but nonmalignant disease – pulmonary arterial hypertension?
Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488287/
Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. - PubMed - NCBI
http://www.ncbi.nlm.nih.gov/pubmed/23513067
Billion dollar rewards for new antibiotics called for to defeat catastrophic rise of superbugs
http://flip.it/BDQT3
CTIX has the technology to prevent the apocalypse with its defensin mimetic technology!
England’s chief medical officer warns of ‘antibiotic apocalypse’:
http://flip.it/2LB2_
See below for refutation:
http://www.fdareview.org/03_drug_development.php
More regarding Dr Farraye
http://www.bumc.bu.edu/medicine/dom-introduction/faculty/farraye/
Don't forget our pipeline autism compound
KM -391
http://cellceutix.com/autism/#sthash.NgY6eHqk.dpbs
Pardon , should have said defensin mimetics in prior post was typing on my phone
Interesting article on potential uses of peptidomimetics in addition to antibiotic uses including antiviral and anti neoplastic uses. With our technology obtained from UPenn to formulate new defensive mimetics, prospects for our technologies and their potential effect on medicine and health throughout the world are amazing!
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155802/#!po=34.7561
Facebook post from cellceutix earlier today:
http://www.eurekalert.org/pub_releases/2016-03/labr-pws032816.php
Did Leo always talk about the use of prurisol in both "mild-to-moderate psoriasis and moderate-to-severe psoriasis, " or is this a change in his verbiage in which he now is including more severe psoriasis manifestations.
If this is a change could it be a hint that now it works with moderate psoriasis so we will evaluate it in more severe subtypes?
This is a prepublication report from the National Academy of medicine providing recommendations and information about the future direction of ovarian cancer treatment .
In particular note emphasis on diagnostics and mention of adaptive trial design
Please see recommendation 1 of the panel on pg 7 in the 2nd link, mutations pg 67 and 71 in 3rd link,mutation pg 171 and adaptive trial design pg 184 in the 4th link.
A prophylactic role for kevetrin? Could it prevent chemo induced AML and myelodysplastic syndrome?
http://genome.wustl.edu/articles/detail/genetic-errors-linked-to-aging-underlie-leukemia-that-develops-after-cancer-treatment/
http://www.nature.com/nature/journal/v518/n7540/abs/nature13968.htm
Direct effect on tumor cells = efficacy. Note how Leo states we met our goals in the 1/29 update to shareholders, then only describes how we met the primary goal of safety. He does not discuss the secondary goal of efficacy but states we will enroll additional patients to FURTHER examine the direct effect on tumor cells. Likely this is to FURTHER corroborate / prove /confirm EFFICACY - the secondary goal of the study.
Current treatment for pancreatic cancer depends on whether the disease at diagnosis is resectable, borderline resectable , unresectable without distant metastasis , or metastatic. If resectable patients usually get adjuvant chemoradiation . If borderline respectable due to extension to nearby vasculature ,neoadjuvant chemoradiation is often used to hopefully facilitate subsequent resection. If unresectable, chemoradiation or chemotherapy alone is used depending on institutional preference and the patients condition. If metastatic, then chemotherapy is used if the patients performance status allows. The radiation course is a 5 to 6 week course of 5 day per week radiation. Chemotherapy is usually a 5FU or Gemcitabine based regimen. The intent of chemoradiation (chemo and radiation are given concurrently) is for chemotherapy to make radiation more effective in killing the cancer then radiation alone – for chemotherapy to work as a radiation sensitizer.
Survival per SEER database: Please see survival stats in: http://seer.cancer.gov/statfacts/html/pancreas.html
Note 9% of patients have disease limited to pancreas without nodal spread and these patients have 5 year survival 27%, 28 % have regional nodal spread with survival approximately 11% at 5 years, most have distant spread with less then 2.5 % 5 year survival.
Kevetrin has great potential to work synergistically with other chemotherapeutic agents based on recent preclinical data http://cellceutix.com/cellceutix-releases-data-used-in-receiving-fda-orphan-drug-designation-of-kevetrin-for-pancreatic-cancer/#sthash.ACfoZ6W9.dpbs
and as a radiosensitizer based on earlier preclinical data (please see my last Post# 137273 -the post I responded to) .I hope kevetrin will enable a future for these patients, giving them life and thus changing the world.
Kevetrin induces cell cycle arrest at G2/M phase of cell cycle see below
http://cellceutix.com/cellceutix-makes-breakthrough-in-cancer-research-by-activating-p53-the-guardian-angel-of-the-human-genome-2/#sthash.edsY0CLz.dpbs
This makes kevetrin likely a great radiation sensitizer as it leaves the cell in it most radiosensitive portion
http://www.ncbi.nlm.nih.gov/pubmed/15234026
Note this US company was supplying it to the aforementioned distributorship in Europe
http://www.adooq.com/kevetrin-hcl.html
This US company states it is for lab research only
More information about the company listing kevetrin for sale:
http://www.hoelzel-biotech.com/en/about-us.html
I recently found a link to what appears to be a relatively reputable European company selling Kevetrin. http://www.hoelzel-biotech.com/en/adooq-inhibitors-other-a13797-10-kevetrin-hcl-10mg.html
I sent a copy of this link to info@cellceutix.com on 1/9/16 to inform them about this issue, wondering if this was an illegal knockoff product, but received no reply. Could this reflect distribution for a pending international trial?
XOC
This book linked below describes several possible drugs affecting p53 including kevetrin and the possible utility of drugs affecting p53 in neuroblastoma
patients -another possible pediatric trial for kevetrin in the future?
https://books.google.com/books?id=63m0CgAAQBAJ&pg=PA45-IA16&lpg=PA45-IA16&dq=derivation+of+the+butyronitrile+and+kevetrin&source=bl&ots=jh6VT9KVOh&sig=gByaeTjcGo77rK3vM30Nqw8SOZE&hl=en&sa=X&ved=0ahUKEwiG7bCv7ZzKAhVLpB4KHfPHB3wQ6AEIFjAD#v=onepage&q=derivation%20of%20the%20butyronitrile%20and%20kevetrin&f=false
XOC
What about the possibility of a blended trial design, is that still possible?
Uses for PolyCide go far beyond just the Healthcare arena:
"In addition to its phase II therapeutic programs PolyMedix leverages its antibiotics expertise by developing PolyCide , synthetic antimicrobial materials for use in personal care articles, cosmetics, plastics, textiles and other materials to create self-sterilizing products and surfaces."
http://www.industrycortex.com/datasheets/profile/1251365876/polycide-fact-sheet-polycide-antimicrobial-materials-fact-sheet
I am not sure if these links were posted regarding polycides from Polymedix. The second link just indicates some potential uses as I coukd not find the fact sheet itself .
http://www.polymedix.com/pipeline/polycide
http://www.industrycortex.com/datasheets/profile/1251365876/polycide-fact-sheet-polycide-antimicrobial-materials-fact-sheet
It seems that I also reposted the link, I was unaware of your posting. We both are lucky to have such a great company with much promise for our due diligence .
Polycide efficacy in suture coatings published in article linked below
http://globenewswire.com/news-release/2012/09/05/488925/10004018/en/Data-Showing-Effectiveness-of-PolyCide-Antimicrobial-in-Surgical-Suture-Coatings-Published-in-American-Chemical-Society-Journal-Langmuir.html
Xoc
Polymedix implant reference attached- Perhaps this article can clarify the use of antibiotic polymers in implants for you - please see references to polymedix implants on page 5 and on the bottom of page 7 in this article.
https://www.dropbox.com/s/4tc5t1gj0yhchp1/-Imported-%20SurfacesNLOct-Nov10.pdf?dl=0
The previous incomplete post was sent in error. I hope that the final secondary outcome measures from the study at Dana Farber will substantiate the tidbits of information we have already been given about the response of these late stage tumors to Kevetrin. I hope that many patients, especially at at higher dose levels. will have disease stabilized or will exhibit partial or complete responses to kevetrin . If this happens, especially given the reputation of the institution in which the study is coming from, we will all soon benefit greatly with a surge in stock price. The slow pace of the trial will be worth it.
If the final secondary outcome measures equal or better the tidbits of information we received to date, especially when
I have been a long for many years, dollar cost averaging my price per share up and even purchasing some shares close to its peak price per share . I do not regret a single purchase as I know what I own. Buying at the current price per share to me is like picking up a diamond that just fell on the floor before others notice it's shine. I believe the floor will not fall further and that the shine of this company will soon be seen by the world as it takes note when news comes out . Soon all of my shares will be viewed by others wishing they had seen a glint of this companies true value earlier.
XOC
Be careful whose remarks you react to. Subtle negative innuendo said in the guise of a helping friend may be a shorters calling card. It would be best if readers of investing blogs read multiple postings from a blogger before reacting in fear and taking what may in fact be only self-serving advice. A discussion between bloggers may also not reflect the sentiment of the majority of shareholders. Such a discussion may reflect their mutual wish to short a company. React cautiously and with knowledge in the market. Read about a company and learn about its on going and pending studies. Go to its web site. Analyze the company yourself. Due diligence is the key. Know what you have or might purchase. The opportunity of a lifetime may in fact be available for a pittance.
Xoc
Terms of license per Edgar
http://www.marketwatch.com/story/10-q-cellceutix-corp-2014-05-12
Interesting article on properties of natural defensins reflecting likely similar utility in the defensins mimetics:
http://journal.frontiersin.org/article/10.3389/fimmu.2012.00249/full